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Autism spectrum disorder (ASD) is multifactorial, with both genetic as well as environmental factors
working in concert to develop the autistic phenotype. Immunological disturbances in autistic individuals
have been reported and a role for food allergy has been suggested in ASD. Single gene mutations in
mammalian target of rapamycin (mTOR) signaling pathway are associated with the development of ASD
and enhanced mTOR signaling plays a central role in directing immune responses towards allergy as well.
Therefore, the mTOR pathway may be a pivotal link between the immune disturbances and behavioral
deﬁcits observed in ASD. In this study it was investigated whether the mTOR pathway plays a role in food
allergy-induced behavioral and immunological deﬁcits.
Mice were orally sensitized and challenged with whey protein. Meanwhile, cow's milk allergic (CMA)
mice received daily treatment of rapamycin. The validity of the CMA model was conﬁrmed by showing
increased allergic immune responses. CMA mice showed reduced social interaction and increased re-
petitive self-grooming behavior. Enhanced mTORC1 activity was found in the brain and ileum of CMA
mice. Inhibition of mTORC1 activity by rapamycin improved the behavioral and immunological deﬁcits of
CMA mice. This effect was associated with increase of Treg associated transcription factors in the ileum of
CMA mice.
These ﬁndings indicate that mTOR activation may be central to both the intestinal, immunological, and
psychiatric ASD-like symptoms seen in CMA mice. It remains to be investigated whether mTOR can be
seen as a therapeutic target in cow's milk allergic children suffering from ASD-like symptoms.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The mammalian target of rapamycine (mTOR) is an evolution-
arily conserved phosphatidylinositol-3-OH kinase (PI(3)K)-related
kinase that plays a central role in the regulation of cell growth and
metabolism (Wullschleger et al., 2006), protein synthesis, cell
proliferation and survival (Hay and Sonenberg, 2004). mTOR acts as
the core subunit of two functionally distinct multi-protein signaling
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2, Utrecht Institute for Phar-
iversity, Universiteitsweg 99,
ld).
Ltd. This is an open access article u(mTORC2) (Hay and Sonenberg, 2004; Sengupta et al., 2010;
Wullschleger et al., 2006). The activation of mTORC1 by immuno-
logical and environmental cues is mediated through the PI3K/Akt
signaling pathway leading to phosphorylation and inhibition of
tuberous sclerosis complex 2 (TSC2) and the subsequent suppres-
sion of GTPase activity of RHEB (RAS homolog enriched in brain),
which directly stimulates the catalytic activity of mTOR in mTORC1
(Fig. 1). Stimulation of mTOR in mTORC1 causes the phosphoryla-
tion of the two translational regulators: protein p70 S6 kinase (p70
S6K) and the eIF-4E binding protein 1 (4E-BP1) (Fig. 1). In this way,
mTORC1 regulates protein synthesis and cell growth (Fingar and
Blenis, 2004). Recent ﬁndings in animal models showed that
mTOR activity gain-of-function mutations in tuberous sclerosis
complex (TSC) (Ehninger et al., 2008), phosphatase and tensin
homolog (PTEN) (Kwon et al., 2006; Zhou et al., 2009) and Fragile Xnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic illustration of mTORC1 pathway. mTORC1 activation starts with the
binding of antigen, costimulatory molecules, cytokines, toll like receptor ligands, and
growth factors to the receptor on the cell membrane, leading to the phosphorylation
and activation of PI3K and AKT. AKT inhibits TSC2 activity by phosphorylation, which
suppresses GTPase activity of RHEB. RHEB directly induces mTOR phosphorylation and
thereby the formation of mTORC1, eventually leading to the phosphorylation of two
downstream effectors: p70 S6K and 4E-BP1. In this ﬁgure, activating phosphorylation
events are indicated by arrows, while inhibitory phosphorylation events are indicated
by ﬂat-ended lines.
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all strongly associated with neurodevelopmental disorders
including autism spectrum disorders (ASD). Rapamycin treatment
in these genetic murine models for ASD was shown to rescue the
ASD-related behavioral deﬁcits and several neurological impair-
ments by targeting the altered mTOR signaling pathway (Ehninger
et al., 2008; Zhou et al., 2009).
The etiology of most neuropsychiatric disorders, including ASD,
is considered to be caused by an interaction of genetic disturbances
and environmental factors. Currently, disturbances in the immune
system, such as those leading to food allergy, are proposed as an
important environmental risk factor (Kennedy et al., 2012;
Theoharides, 2013). Increasing evidence suggests that the im-
mune disturbances in the gastrointestinal tract of patients with
ASD can inﬂuence brain functioning via a number of pathways that
connect the brain and the gut (Kennedy et al., 2012). Recently, it
was also demonstrated that cow's milk allergic mice display ASD-
like behavioral and neurochemical deﬁcits (De Theije et al.,
2014b). However, more research is needed to elucidate the under-
lying mechanism regarding the correlation of the gastrointestinal
immune problems with ASD.
Currently, more evidence is emerging that apart from the
involvement in neurological disorders, mTOR signaling pathway
also plays an important role in immunological function. mTOR isknown to have a role in macrophage polarization (Byles et al.,
2013), regulating T cell balance and survival (Delgoffe et al., 2011),
differentiation (Delgoffe et al., 2011), function and activation of
mast cells (Kim et al., 2009). Therefore, the current study investi-
gated the involvement of mTOR signaling pathway in behavioral
changes as well as allergic immune responses and the development
of Treg cells in CMA mice. The effect of rapamycin on enhanced
mTOR signaling pathway in the brain as well as in the intestine was
examined.2. Methods and materials
2.1. Animal model and treatment protocols
Three-week-old pathogen free male C3H/HeOuJ mice were purchased from
Charles River Laboratories (L'Arbresle Cedex, France) and housed at the animal fa-
cility of Utrecht University. Mice were fed a cow's milk free diet (Special Diet Ser-
vices, Witham, UK). The murine model of CMAwas induced as described previously
(Fig. 2A) (De Theije et al., 2014b; Schouten et al., 2010). In short, micewere sensitized
intragastrically (i.g.) with 20 mg whey (DMV International, Veghel, The
Netherlands)/0.5 mL PBS (Cambrex Bio Science, Verviers, Belgium) containing 10 mg
cholera toxin (CT, List Biological Laboratories, Campbell, CA, USA) as an adjuvant.
Sham-sensitized mice received CT alone. Mice were sensitized once a week for 5
consecutive weeks. One week after the last sensitization, sham and whey-sensitized
mice were challenged i.g. with 50 mg whey/0.5 mL PBS and behavioral tests were
conducted the next day. Rapamycin (LC laboratories, Woburn, MA, USA) was dis-
solved in 100% ethanol, stored at a stock concentration of 20 mg/mL in aliquots
at 20 C. Prior to each administration, working solutions of rapamycin were pre-
pared in 5% Tween-80 (SigmaeAldrich, Zwijndrecht, The Netherlands), 5% PEG 400
(SigmaeAldrich, Zwijndrecht, The Netherlands), and 4% ethanol (SigmaeAldrich,
Zwijndrecht, The Netherlands). Mice, CMA and control groups, were injected
intraperitoneally with either rapamycin (0.5 mg/kg, 2 mg/kg or 4 mg/kg body
weight) or vehicle once per day for 5 consecutive days per week. The results
described in this report were obtained from 2 independent experiments (Fig. 2B).
All animal procedures were approved by and conducted in accordance with the
guidelines of the Animal Ethics Committee of Utrecht University (approval number:
2011.I.04.045 and 2012.I.04.054).2.2. Behavioral tests
Social interaction test and grooming tests were performed as described previ-
ously (De Theije et al., 2014b). In short, mice were individually placed in a
45  45 cm open ﬁeld, with a small perforated Plexiglass cage (10 cm diameter)
located against one wall allowing visual, olfactory and minimal tactile interaction
(Fig. 3A). Mice were habituated to the open ﬁeld for 5 min and an age- and gender-
matched unfamiliar target mouse was introduced in one of the cages for an
additional 5 min. By using video tracking software (EthoVision 3.1.16, Noldus,
Wageningen, The Netherlands), an interaction zone around the cage was digitally
determined. Time spent in the interaction zone, latency until ﬁrst occurrence in the
interaction zone, and total distance moved were measured. In addition, the mice
were scored for spontaneous grooming behaviors as described earlier (Crawley,
2012; Kas et al., 2014). Each mouse was placed individually in an empty home
cage (35 cm  20 cm) without bedding and video recordings were used for
behavioral scorings of frequency and cumulative time spent grooming all body re-
gions. After a 5 min habituation period in the cage, each mouse was scored for 5 min
by two independent researchers who were blinded for treatment schedule. Inter-
rater reliability was 99%. Open ﬁeld was cleaned with water followed by 70%
ethanol after each test.2.3. Measurements of serum mMCP-1 and whey-speciﬁc immunoglobulins
16 Hours after oral challenge, blood of mice was collected and centrifuged for
20 min at 14,000 rpm. Serum was collected and stored at 70 C. Concentration
of mouse mast cell protease-1(mMCP-1) in serum was measured by commer-
cially available ELISA kits (Moredun Scientiﬁc Ltd., Penicuik, UK) according to the
manufacturer's protocol. Concentrations of whey-speciﬁc immunoglobulins IgE,
IgG, and IgG2a in serum were measured by ELISA according to the protocol
described previously (De Theije et al., 2014b). Biotin-labeled rat anti-mouse IgE,
IgG1 and IgG2a were purchased from BD Biosciences (Alphen aan den Rijn, The
Netherlands). Microlon plates were purchased from Greiner (Alphen aan den
Rijn, The Netherlands). Carbonate/bicarbonate buffer was purchased from Sig-
maeAldrich (Zwijndrecht, The Netherlands). Streptavidin-horse radish peroxi-
dase was purchased from Sanquin (Amsterdam, The Netherlands). O-
phenylendiamine was purchased from SigmaeAldrich (Zwijndrecht, The
Netherlands). Microplate reader was obtained from Bio-Rad (Veenendaal, The
Netherlands).
Fig. 2. Schematic representation of experimental design (A) and overview of treatment groups (B).
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After sacriﬁcing, brains and intestinal tissues were immediately isolated from
mice and snap frozen in 2-methylbutane (SigmaeAldrich, Zwijndrecht, The
Netherlands) and dry ice, stored at 70 C after the dissection. Coronal slices of
500 mm were sectioned using a cryostat (Model700, Lameris Instruments, Utrecht,
The Netherlands). Then bilateral brain regions (prefrontal cortex, amygdala, dorsal
hippocampus, somatosensory cortex) were isolated from the coronal slices using a
scalpel. To prepare lysates, frozen tissues were sonicated in lysis buffer containing
RIPA buffer (Fisher Scientiﬁc, Landsmeer, The Netherlands), complete mini protease
inhibitor cocktail tablets (Roche, Almere, The Netherlands), benzonase nuclease
(Calbiochem, Amsterdam, The Netherlands), AEBSF (Calbiochem, Amsterdam, The
Netherlands), and phosphatase inhibitor cocktail (Calbiochem, Amsterdam, The
Netherlands). Homogenate was centrifuged at 14,000 rpm for 20 min andFig. 3. (A) Schematic representation of the social interaction test. CMA mice showed reduced
interaction mouse for the ﬁrst time as compared to control (C). The mobility of these mice w
(D). Rapamycin treatment reversed the social behavior of CMA mice. One-way ANOVA follow
as mean time (s) ± SEM for (B) and mean distance moved (cm) ± SEM for (D) from two inde
test was conducted for (C) as latency in interaction zone was not normally distributed. *P < 0
CMA with 2 mg/kg Rapa: P ¼ 0.5051; CMA vs CMA with 4 mg/kg: P ¼ 0.4177.supernatant was collected. Protein concentration was determined using BCA kit
(Pierce, Rockford, USA). For western blotting, 30 mg of sample was loaded onto
Criterion TGX precast gel (Bio-Rad, Veenendaal, The Netherlands), and blotted
overnight onto PVDFmembrane (Bio-Rad, Veenendaal, The Netherlands), whichwas
blocked in 5% nonfat dry milk for 1 h. Subsequently, membranes were washed with
TBS/0.1% Tween-20 (SigmaeAldrich, Zwijndrecht, The Netherlands) 3 10 min and
incubated overnight with the primary antibodies (1:1000) at 4 C. The primary
antibodies against phospho-mTOR (Ser2448, #5536), mTOR (#2972), phospho-AKT
(Ser473, #4060), AKT (#9272), phospho-p70 S6K (Thr389, #9205), p70 S6K (#9202),
phospho-4E-BP1 (Thr37/46, #9459), and 4E-BP1 (#9452) were from Cell Signaling
Technology, Leiden, The Netherlands. The primary antibody against GAPDH
(#3777R-100) was from Biovision, Uithoorn, The Netherlands. Afterward, the
membranes were washed with TBS/0.1% Tween-20 3 10 min and incubated with
the secondary antibody polyclonal HRP-conjugated goat anti-rabbitsocial interaction (B) and it took signiﬁcantly more time for CMA mice to approach the
as hardly affected in both habituation phase (no target) and interaction phase (target)
ed by a Bonferroni's multiple comparisons test was conducted and data are presented
pendent experiments. KruskaleWallis test followed by a Dunn's multiple comparisons
.05. **P < 0.01. n ¼ 7e17 per group. (C) CMA vs CMAwith 0.5 mg/kg: P ¼ 0.5879; CMA vs
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noreactive bands were detected by ECL prime kit (Health Care, Amsterdam, The
Netherlands) and the results were normalized with GAPDH or the non-
phosphorylated corresponding protein using quantitative densitometry (Bio-Rad,
Veenendaal, The Netherlands) and reported as relative band densities. Membranes
were reprobed for a maximal of 3 times with different primary antibodies after
stripping the membranes with Restore Western Blot Stripping buffer (Pierce,
Rockford, USA)).
As shown in Figs. 6 and 7, the primary antibody against phospho-p70 S6K
(Thr389) detects endogenous p70 S6K as well as p85 S6K. P70 S6K is functionally
relevant for mTOR signaling pathway as this protein is required for cell growth and
G1 cell cycle grogression (Pullen and Thomas, 1997). We measured the phosphor-
ylation of p70 S6K as an readout for mTORC1 activation.
2.5. mRNA expression analysis
After sacriﬁcing, the distal part of the jejunum and Peyer's patches were isolated
and stored at 70 C until further analysis. The total RNA was isolated using the
RNAeasy kit (Qiagen, Germantown, MD, USA) and stored at 20 C. Afterward, the
total RNA was reverse transcribed into cDNA using the iScript cDNA synthesis kit
(BioRad, Hercules, CA, USA). After cDNA synthesis, real-time PCR was performed
using iQ SYBR Green supermix kit (Bio-Rad, Hercules, CA USA) with the CFX 96 Real-
time system (BioRad, Hercules, CA USA). Ribosomal protein S13 (Rps13) was used as
reference gene. Relative target mRNA was calculated by applying the formula:
relative mRNA expression ¼ 2Ct[Rps13] e Ct[target mRNA] (García-Vallejo et al., 2004).
Primers for interleukin (IL) 10, transforming growth factor (TGF)-b and Foxp3 were
commercially purchased from SABiosciences-QiagenGmbH (Hilden, Germany).
2.6. Statistical analysis
Experimental results are expressed as mean ± S.E.M. In general, differences
between groups were statistically determined with a one-way ANOVA followed by a
Bonferroni's multiple comparisons test. Log transferred data were used to obtain
normality for one-way ANOVAwhen analysing the following data: whey-speciﬁc IgE
level, whey-speciﬁc IgG1 level, whey-speciﬁc IgG2a level, and mouse mast cell
protease-1. As latency in interaction zone (social interaction test) did not have
normal distribution, data were analyzed with KruskaleWallis test followed by a
Dunn's multiple comparisons test. Results were considered statistically signiﬁcant
when P < 0.05. Analyses were performed using GraphPad Prism, version 6.02.
3. Results
3.1. mTOR signaling pathway is implicated in the reduced social
interaction and increased repetitive behavior of cow's milk allergic
mice
Previous studies using mice mutant for genes in the mTOR
signaling pathway, have shown that activation of mTOR can
contribute to the development of autistic phenotypes observed in
ASD and related neurodevelopmental disorders (Ehninger et al.,
2008; Kwon et al., 2006; Nimchinsky et al., 2001; Zhou et al.,
2009). In a previous study using a murine model of CMA, de
Theije and coworkers showed that whey-allergic mice displayed
reduced social interaction and increased repetitive behavior
compared to sham-sensitized control mice (De Theije et al., 2014b).
To investigate the involvement of the mTOR signaling pathway inFig. 4. CMA mice showed signiﬁcantly enhanced grooming duration (A) and frequency (B
Rapamycin treatment normalized the grooming duration dose-dependently and reduced the
comparisons test was conducted and data are presented as mean duration (s) ± SEM for A
0.5 mg/kg: P ¼ 0.2274.the behavioral changes seen in whey-allergic mice, CMAmice were
treated with different doses of rapamycin and it was analyzed
whether this treatment did inﬂuence behavioral tests after oral
challenge with whey. Both social interaction as well as self-
grooming behavior were investigated. CMA mice spent less time
with the interaction mouse compared to the control mice and
rapamycin treatment normalized the reduced social interaction
(Fig. 3B). CMA mice also showed an increased latency of ﬁrst
approach to the interaction mouse compared to control mice and
rapamycin reversed this increased latency (Fig. 3C). In both the
habituation phase (no target) and the interaction phase (target),
induction of allergy did not affect locomotor activity which was
unaltered upon rapamycin treatment of the allergic mice as well
(Fig. 3D). In addition, the data of control groups were analyzed
separately from CMA groups. In both the habituation phase (no
target) and the interaction phase (target), rapamycin had no sig-
niﬁcant effects on latency in interaction zone and total distance
moved in control groups.
Besides social interaction, the novelty-induced self-grooming
behavior of the mice was scored, which is a representative of re-
petitive behavior (Crawley, 2012, 2007; McFarlane et al., 2008).
Grooming was assessed in the second experiment in which 0.5 and
2mg/kg rapamycin have been tested. Groomingwas not assessed in
mice treated with the higher dose of rapamycin (4 mg/kg) because
no additional effects were expected based on previous proof of
concept studies that were focused on immune parameters (see
Results Section 3.2) and social interaction (see Fig. 3). CMA mice
displayed increased cumulative grooming time and grooming fre-
quency compared to sham-sensitized control mice. Rapamycin
reversed the grooming duration dose dependently (Fig. 4A) and
reduced grooming frequency (Fig. 4B) of CMA mice.
3.2. mTOR signaling pathway and CMA immune responses
To assess whether the mTOR signaling pathway was involved in
whey-induced allergic immune responses, whey-speciﬁc serum
immunoglobulins have been analyzed. The whey-speciﬁc serum
IgE, IgG1, and IgG2a levels were signiﬁcantly increased in whey-
sensitized and challenged mice in comparison to that of sham
(non)-sensitized mice. Rapamycin suppressed the increased whey-
speciﬁc immunoglobulin serum levels in CMA mice (Fig. 5AeC).
To further investigate the effect of rapamycin on whey-induced
allergic immune response, mucosal mast cell degranulation was
analyzed by measuring mMCP-1 concentrations in serum. mMCP-1
is a protease derived from the mucosal mast cells and is released in
the blood stream after mast cell degranulation (Pemberton et al.,
2006; Wastling et al., 1998). The mMCP-1 concentration was
augmented in the serum of CMA mice in comparison to that of) as compared to control, indicating the enhanced repetitive behavior of CMA mice.
grooming frequency of CMA mice. One-way ANOVA followed by a Bonferroni's multiple
and mean frequency ± SEM for B. *P < 0.05, n ¼ 10 per group. (B) CMA vs CMA with
Fig. 5. Effect of rapamycin treatment on whey-induced allergic immune responses in CMA mice and sham-sensitized control mice. CMA mice showed signiﬁcantly increased serum
levels of arbitrary units (AU) of whey-speciﬁc immunoglobulin IgE (A), IgG1 (B), IgG2a (C) and serum concentration of mouse mast cell protease-1 (D). Rapamycin treatment
inhibited the allergic immune responses of CMA mice. Data were log transferred to obtain normality. One-way ANOVA followed by a Bonferroni's multiple comparisons test was
conducted and data are presented as Box-and-Whisker Turkey plots. *P < 0.05, ***P < 0.001, ****P < 0.0001, n ¼ 7e17 per group. (A) CMA vs CMAwith 4 mg/kg Rapa: P ¼ 0.1190. (D)
CMA vs CMA with 4 mg/kg Rapa: not signiﬁcant.
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degranulation in the whey-allergic mice. The inhibition of mTOR
with rapamycin suppressed mast cell degranulation as indicated by
reduced mMCP-1 serum levels in CMA mice (Fig. 5D).
3.3. CMA is associated with enhanced mTOR signaling in the
prefrontal cortex and amygdala
Since enhanced mTOR signaling is implicated in a number of
neurodevelopmental disorders including ASD, the question
whether mTOR signaling was enhanced in speciﬁc brain regions of
whey-allergic mice was raised. To address this question, western
blotting technologies were used to measure the phosphorylation of
mTOR-related proteins in the prefrontal cortex, amygdala, dorsal
hippocampus, and somatosensory cortex of the mice. The phos-
phorylation of p70 S6K and 4E-BP1 was increased in prefrontal
cortex and amygdala of CMA mice compared to sham-sensitized
control mice (Figs. 6B,C & EeG and 7B,C & EeG). Rapamycin
reduced the enhanced phosphorylation of p70 S6K and 4E-BP1 in
prefrontal cortex and amygdala of CMA mice (Figs. 6B,C & EeG and
7B,C & EeG). The phosphorylation of mTOR (Figs. 6D & H and 7D &
H) or AKT (Figs. 6I and 7I) was not signiﬁcantly changed in the
prefrontal cortex and amygdale of CMAmice as compared to that of
sham-sensitized control mice.
The extent of phosphorylation of p70 S6K in the prefrontal
cortex and amygdala is also shown to correlate with the extent of
social interaction (Figs. 6J and 7J). Overall, no effects of CMA or of
rapamycin were observed on mTOR signaling pathway proteins in
dorsal hippocampus and somatosensory cortex of the mice (data
not shown).
3.4. Rapamycin inhibited the enhanced p70 S6K activity and
increased the development of Treg cells in the ileum of CMA mice
mTOR is known to play an essential role in directing immune
responses. To investigate the activity of mTOR in the whey-inducedallergic response, the phosphorylation of mTOR signaling proteins
was examined in the ileum of CMA mice and compared to that of
control mice. The phosphorylation of p70 S6K was signiﬁcantly
increased in ileum of CMA mice compared to that of sham-
sensitized control mice (Fig. 8). Comparable to the observations
in the brain, rapamycin inhibited the enhanced phosphorylation of
p70 S6K in the distal ileum of CMA mice (Fig. 8A and B). The
phosphorylation of mTOR was not signiﬁcantly affected by CMA or
rapamycin (Fig. 8A and C). To examine the involvement of mTOR
signaling pathway in the differentiation and in the development of
the regulatory immune responses, mRNA expression of Treg asso-
ciated transcription factor Foxp3 was analyzed in ileum and Peyer's
patches of mice. The mRNA expression level of Foxp3 in the ileum,
but not in the Peyer's patches, of CMAmice was lower compared to
that in control mice, although not signiﬁcantly (Fig. 9). Treatment
with rapamycin signiﬁcantly increased the mRNA expression level
of Foxp3 both in the ileum (Fig. 9A) and in the Peyer's patches of
CMA mice (Fig. 9B). To further examine the effect of rapamycin on
the production of Treg cell associated anti-inﬂammatory cytokines,
the production of speciﬁc cytokines was analyzed in the ileum.
Levels of anti-inﬂammatory interleukin (IL)-10 (Fig. 9C) and
transforming growth factor (TGF)-b (Fig. 9D) were elevated by
rapamycin treatment, although not signiﬁcantly. Furthermore, a
correlation between the extent of phosphorylation of p70 S6K and
of Foxp3mRNA expression in the ileumwas demonstrated (Fig. 9E).
Foxp3 mRNA expression in the ileum also positively correlates with
social interaction (Fig. 9F).
4. Discussion
The current study investigated the involvement of the mTOR
signaling pathway in the autistic-like behavior as well as in the
immunological changes induced by cow's milk allergy in mice. It
was demonstrated that induction of CMA induces reduced social
behavior and increased repetitive behavior. Rapamycin inhibited
the enhanced mTOR signaling pathway both in the brain and in the
Fig. 6. Western blot analysis showed signiﬁcantly increased phosphorylation of p70 S6K and 4E-BP1 in the prefrontal cortex of CMA mice and the phosphorylation of mTOR and
AKT was hardly affected. The gray area in Figure A indicates prefrontal cortex. Figure B and E are typical examples of western blots. Rapamycin treatment inhibited the CMA-induced
activation of p70 S6K and of 4E-BP1 in the prefrontal cortex. Densities of phosphorylation of p70-S6K, 4E-BP1, mTOR, and AKT were divided by the corresponding density of the
GAPDH signal (C & D) or the non-phosphorylated corresponding protein (FeI). Figure J shows that the enhanced phosphorylation of p70 S6K in the prefrontal cortex is associated
with reduced social interaction. One-way ANOVA followed by a Bonferroni's multiple comparisons test was conducted and data are presented as mean relative density ±SEM.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, (C,D, F & HeI) n ¼ 4 per group. (G) n ¼ 3 per group.
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Fig. 6. (continued).
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inhibition of mTOR signaling pathway by rapamycin treatment also
resulted in the suppression of allergic immune responses and
resulted in an enhanced number of Treg cells in the ileum of CMA
mice. By showing improvement of the ASD-like phenotype upon
treatment with rapamycin, it was validated that mTOR plays a
pivotal role in causing the behavioral phenotype and immunolog-
ical changes seen in CMA mice.
ASD are characterized by a series of behavioral deﬁcits including
reduced social behavior, stereotyped or repetitive behavior (Lord
et al., 2000). Previous studies demonstrated that the induction of
cow's milk allergy in mice, characterized by the induction of whey-
speciﬁc immunoglobulin levels as well as by mast cell degranula-
tion, can cause ASD-like behavioral symptoms including reduced
social interaction and increased repetitive behavior (De Theije et al.,
2014b). The present study demonstrated that rapamycin treatment
improved the autistic-like behavior of CMA mice. The induction of
allergy was accompanied by biochemical changes in the prefrontal
cortex and amygdala as assessed by monoamine and its metabolite
levels (De Theije et al., 2014b). The present study demonstrated that
these biochemical changes also involve the enhanced mTOR
signaling pathway, which has recently emerged as a central regu-
lator of ASD-like behavioral symptoms.
Emerging evidence suggests that dysregulation of the brain-gut
communication can result in gastrointestinal disorders, and in
behavioral problems as well (Kennedy et al., 2012). Theinvolvement of gastrointestinal disorders in ASD has been sug-
gested (De Theije et al., 2014a, 2014b). Studies showed that both
IgE-mediated and non-IgE-mediated allergic immune responses
are associated with ASD symptoms (Theoharides et al., 2012). The
exact patho-physiological relationship between the gastrointes-
tinal and behavioral co-morbidities is yet unknown. In ASD, several
risk genes have been identiﬁed that are part of or directly linked to
the mTOR signaling pathway (Ehninger et al., 2008; Kwon et al.,
2006; Nimchinsky et al., 2001; Zhou et al., 2009). Furthermore,
enhanced mTOR activity plays a central role in directing immune
responses towards allergy (Kim et al., 2009). Rapamycin inhibited
the enhanced levels of whey-speciﬁc IgE, IgG1, and IgG2a in the
serum of CMAmice. It needs to be further investigatedwhether this
also leads to a relevant decrease in allergic symptoms. The mTORC1
pathway has been demonstrated to be involved in the function of
mast cells and controls cell survival and/or growth (Kim et al.,
2009). In a separate in vitro study we observed that antigen-IgE-
mediated mast cell activation resulted in enhanced mTOR
signaling and that rapamycin was able to reduce the acute
degranulation as well as the cytokine production at 4 h (personal
observation). Similar results were shown in vivo in this present
study, demonstrating that rapamycin inhibited the CMA-associated
mast cell degranulation.
Morphological abnormalities and dysfunctions in various brain
regions, including prefrontal cortex and amygdala, have been found
in autistic individuals in numerous clinical and preclinical studies
Fig. 7. Western blot analysis showed increased phosphorylation of p70-S6K and 4E-BP1 in the amygdala of CMA mice and rapamycin treatment inhibited the phosphorylation of
p70-S6K in amygdala of CMA mice. The gray area in Figure A indicates amygdala. Figure B and C are typical examples of western blots. The phosphorylation of mTOR was not
affected by either CMA or rapamycin treatment. Densities of phosphorylation of p70-S6K, mTOR, and AKT were divided by the corresponding density of the GAPDH signal (C & D) or
the non-phosphorylated corresponding protein (FeI). Figure J shows that the enhanced phosphorylation of p70 S6K in the amygdala is associated with reduced social interaction.
One-way ANOVA followed by a Bonferroni's multiple comparisons test was conducted and data are presented as mean relative density ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001. (C-D,
F & HeI) n ¼ 4 per group. (G) Control vs CMA: P ¼ 0.0560. CMA vs CMA with Rapa 0.5 mg/kg: P ¼ 0.4614. CMA vs CMA with Rapa 0.5 mg/kg: P ¼ 0.8803. n ¼ 3 per group.
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2014; Wegiel et al., 2014). The prefrontal cortex is known to play
an important role in the process of cognitive control and the control
of goals-directed thought and behavior (Miller, 2000; Watanabe
and Sakagami, 2007). Damage to corticostriatal circuits in pre-
frontal cortex can result in abnormal repetitive behavior (Langen
et al., 2011), which has been seen in CMA mice. Prefrontal cortex
lesions in monkeys and humans can also lead to impairments in
social and emotional behavior (Szczepanski and Knight, 2014).
Amygdala plays an essential role in social behavior and guiding the
emotions. It was shown that amygdala volume positively correlates
the size and complexity of social network in adult humans (Bickart
et al., 2011). Amygdala lesions impaired social anxiety and social
recognition in mice (Wang et al., 2014). In the current study,upregulation of mTORC1 pathway was found in the prefrontal
cortex and amygdala of CMA mice, which may be associated with
enhanced repetitive behavior and disturbed social behavior
observed in CMAmice. Pharmacologic administration of rapamycin
inhibited the mTORC1 pathway in the prefrontal cortex and
amygdala and reversed autistic-like behavior in CMA mice. In
addition, Ehninger et al. reported that in Tsc2þ/ mice hyperactive
mTOR signaling was shown in hippocampus and that this led to
deﬁcits in hippocampal-dependent learning (Ehninger et al., 2008).
Moreover, it was demonstrated that mTORC1 was highly activated
in Pten mutant mice and rapamycin treatment effectively reduced
mTORC1 signaling in both hippocampus and cortex (Zhou et al.,
2009). The mTORC1 pathway plays central roles in synaptic pro-
tein synthesis (Hay and Sonenberg, 2004; Hoeffer and Klann, 2011).
Fig. 8. CMA mice showed signiﬁcantly increased phosphorylation of p70 S6 kinase in ileum and rapamycin treatment inhibited the phosphorylation of p70 S6 kinase (B). No
difference was observed between the groups regarding the phosphorylation of mTOR (C). Figure A is a typical example of western blots. Density of phosphorylation of p70-S6K and
mTOR was divided by the corresponding density of the GAPDH signal. One-way ANOVA followed by a Bonferroni's multiple comparisons test was conducted and data are presented
as mean relative density ±SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001, n ¼ 5 per group.
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was examined in several brain regions including prefrontal cortex,
amygdala, dorsal hippocampus, and somatosensory cortex. P70 S6K
and 4E-BP1 are the most important downstream effector proteins
of mTORC1 and regulates protein synthesis. Upon induction of
whey allergy in mice, the phosphorylation of p70 S6K and 4E-BP1
seemed to be enhanced in both amygdala and prefrontal cortex,
indicating that the mTORC1 signaling pathway is enhanced in both
brain regions. A hyperactive mTOR pathway leading to aberrant
protein synthesis can result in synaptic dysfunction (Wang and
Doering, 2013). The enhanced phosphorylation of p70-S6K and
4E-BP1 could induce excessive synthesis of synaptic proteins
including neuroligin (NLGN) synthesis (Südhof, 2008; Wang and
Doering, 2013). It has been demonstrated that increased trans-
lation of NLGNs leads to increased ratio of synaptic excitation to
inhibition (E/I), which may eventually be involved in the develop-
ment of autistic phenotypes in CMAmice (Südhof, 2008; Wang and
Doering, 2013). The enhanced phosphorylation levels of p70 S6K at
Thr389 or 4E-BP1 at Thr37/46 also indicate enhanced mTOR ac-
tivity, because these epitopes on p70 S6K and 4E-BP1 are directly
phosphorylated by mTOR. It is known that mTOR phosphorylation
at Ser2448 does not always reﬂect mTOR activity andmTOR activity
is routinely determined bymeasuring the phosphorylation levels of
p70 S6K at Thr389 or 4E-BP1 at Thr37/46 (Caccamo et al., 2010; Das
et al., 2008; Guertin and Sabatini, 2007; Hay and Sonenberg, 2004;
Hay, 2005). The regulation of mTOR has been shown to occur via
multiple phosphorylation sites, namely Ser1261, Thr2446, Ser2448,
and Ser2481 (Acosta-Jaquez et al., 2009). In the current study we
evaluated only the Ser2448 phosphorylation of mTOR as Ser2448 is
involved in the formation of mTORC1 (Copp et al., 2009). However,
Ser2448 was shown to be a feedback site on mTOR from its
downstream target, p70 S6K, which means that p70 S6K is able to
phosphorylate mTOR at Ser2448 and thereby restore Ser2448-
speciﬁc phosphorylation (Chiang and Abraham, 2005). Therefore,
no signiﬁcant change of mTOR phosphorylation on Ser2448 was
observed in CMA mice. mTOR phosphorylation on other sites such
as Ser1261 might be affected more signiﬁcantly after induction of
CMA, because mTOR phosphorylation on Ser1261 is also requiredfor mTORC1 function and mTORC1-mediated substrate phosphor-
ylation, e.g. p70 S6K and 4E-BP1 (Acosta-Jaquez et al., 2009).
Furthermore, rapamycin forms a complex with FK506-binding
protein of 12 kDa (FKBP12) and this complex then binds to mTOR
(Fingar and Blenis, 2004;Wullschleger et al., 2006). The binding site
of FKBP12-rapamycin complex in mTOR is different to the
phosphorylation site of mTOR. Essentially, FKBP12-rapamycin
complex binds to FRB domain of mTOR, while the phosphoryla-
tion site is located at ser2448 close to C-terminal (Fingar and Blenis,
2004; Wullschleger et al., 2006). FKBP12-rapamycin complex binds
directly to the FRB domain of phosphorylated mTOR, blocks the
binding of other structural proteins of mTOR complex 1 and thereby
the formation of mTOR complex 1 (De Theije et al., 2011; Fingar and
Blenis, 2004; Wullschleger et al., 2006). Therefore, the phosphor-
ylation of mTOR was barely affected by rapamycin treatment while
the phosphorylation of mTORC1 downstream effector proteins,
namely p70 S6K and 4E-BP1, was inhibited in the prefrontal cortex
and amygdala of CMA mice, which was directly associated with the
improvement of the behavioral deﬁcits in CMAmice. Because of the
direct inhibition of p70 S6K and 4E-BP1-dependent synaptic
protein synthesis in the prefrontal cortex and amygdala of CMA
mice, rapamycin treatment in the low dose showed more profound
effects on behavioral changes as compared to CMA-associated mast
cell degranulation, which involves a complex interplay of various
intracellular signaling pathways and mTOR signaling pathway is
part of the complex intracellular signaling network (Gilﬁllan and
Tkaczyk, 2006; Sibilano et al., 2014).
A variety of environmental factors have been implicated in the
development of ASD, of interest is intestinal immune disturbances
(De Theije et al., 2014a; Kennedy et al., 2012; Kraneveld et al., 2014;
Meldrum et al., 2012). The mTOR pathwaymay be the link between
the immune disturbances and behavioral deﬁcits observed in ASD.
The current study described that phosphorylation of downstream
effector protein p70 S6K was enhanced in the ileum of CMA mice
and rapamycin inhibited the CMA-induced mTOR activation in the
ileum. Delgoffe GM et al. reported that the low mTORC1 and
mTORC2 activity is required for the development of regulatory
T cells (Delgoffe et al., 2011). In the present study it was found that
Fig. 9. In the ileum of mice undergoing CMA a reduced expression of Foxp3 mRNA was found (A). Suppression of mTOR signaling by rapamycin induced upregulation of Foxp3
mRNA expression in both ileum (A) and Peyer's patches (B) in CMA mice. Rapamycin treatment promoted anti-inﬂammatory IL-10 (C) and TGF-b (D) production in the ileum of CMA
mice. Reduced Foxp3 mRNA expression in the ileum is associated with enhanced phosphorylation of p70-S6 kinase in the ileum (E) as well as social interaction (F). (A) and (B) One-
way ANOVA followed by a Bonferroni's multiple comparisons test was conducted and data are presented as mean relative mRNA expression ± SEM. *P < 0.05, **P < 0.01,
****P < 0.0001. (A) n ¼ 7e12. (B) n ¼ 7. (C) and (D) One-way ANOVA followed by a Bonferroni's multiple comparisons test was conducted to examine the effect of different doses of
rapamycine in CMA. (C) CMA vs CMA with 2 mg/kg Rapa: P ¼ 0.1616, n ¼ 4e5. (D) CMA vs CMA with 2 mg/kg Rapa: P ¼ 0.0730, n ¼ 5.
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scription factor Foxp3, mRNA expression level in the ileum and
Peyer's patches of CMA mice. Previous studies showed that IL-10
and TGF-b were able to suppress T cell activity and support regu-
latory T cells in suppressing airway hyperreactivity and inﬂam-
mation (Jutel et al., 2003; Presser et al., 2008). Elevated mRNA
expression of anti-inﬂammatory IL-10 and TGF-b was demon-
strated in the ileum of CMA mice with rapamycin treatment, indi-
cating that possibly IL-10 and TGF-b are involved in the rapamycin
induced suppression of cow's milk allergy in mice. Rapamycin
treatment induces IL-10 and TGF-b production in the ileum of CMA
mice. These anti-inﬂammatory cytokines might be able to get into
the circulation to reach the brain. Subsequently, the anti-
inﬂammatory cytokines might cross the blood brain barrier via
direct transport or cytokine transporters/receptors on the cell sur-
face and thereby directly interact with brain tissue in the speciﬁc
brain regions (Banks et al., 2002; Banks, 2005). Through this
mechanism the anti-inﬂammatory cytokines might positively
regulate the function of central nervous system, eventually leading
to the improvement of disturbed brain functions and the alleviationof autistic-like behaviors in CMA mice. Furthermore, altered serum
cytokine levels such as IL-4 and interferon gamma (IFNg) in
response to maternal immune activation (MIA) have been found in
MIA mouse model for autism and were shown to play a critical role
in manifestation of behavioral deﬁcits caused by MIA (Onore et al.,
2012, 2014). Of interest is IL4, which is a typical Th2 cytokine
released during allergic responses, such as CMA. Future studies to
examine the role of IL4 and other allergy-associated cytokines in
CMA-induced ASD-like behavior might be of interest, but beyond
the scope of this study. Overall, our results provide additional and
new knowledge in themechanism of how immune regulatory T cell
responses and Tcell activity after rapamycin treatment are linked to
guteimmuneebrain axis, showing potential for the increased
production of anti-inﬂammatory cytokines IL-10 and TGF-b in the
gut of CMA mice to alleviate behavioral deﬁcits.
5. Conclusions
In conclusion, the current studies provide strong and ﬁrst evi-
dence that the enhanced mTOR signaling pathway in the brain as
J. Wu et al. / Neuropharmacology 97 (2015) 220e232 231well as in the intestines plays a pivotal role in the behavioral and
immunological changes in CMA mice. mTOR might be the linking
pin involved in guteimmuneebrain axis in ASD and the intestinal
tract could be a potential target in the treatment of patients with
ASD and comorbid intestinal symptoms. It is a compelling hy-
pothesis that an enhanced mTOR activity throughout the body may
account for both the behavioral as well as the gastrointestinal
dysfunctions in patients with ASD. Whether inhibition of mTOR is
able to treat both allergic and behavioral deﬁcits of ASD patients
remains to be further investigated. Importantly, increased gastro-
intestinal deﬁcits and in particular behavioral abnormalities are
commonly reported in other neurodevelopmental diseases such as
attention deﬁcit hyperactivity disorder (ADHD) (Verlaet et al.,
2014), multiple sclerosis (Lin et al., 2014), schizophrenia(Sev-
erance et al., 2014), Parkinson's disease (Pfeiffer, 2011), however
the role of mTOR needs to be investigated. Our ﬁndings on the
guteimmuneebrain connection in a murinemodel of CMA indicate
that targeting mTOR signaling pathway might be applicable to
various neurological disorders. Future studies focusing on the
mTOR signaling pathway should shed more light on the effective
treatment of ASD and other neurodevelopmental disorders.
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